Date of publication: April 09, 2021

Pursuant to the role of the Health Technology Assessment Council (HTAC) to develop coverage recommendations particularly in the selection and financing of COVID-19 vaccines using the Evaluation Framework set by the HTAC, this report presents all currently available evidence considered in the assessment of COVID-19 Vaccine AstraZeneca. This assessment follows the HTAC evaluation framework to assess COVID-19 vaccines using the following criteria: (1) responsiveness to magnitude and severity; (2) clinical efficacy and safety; (3) affordability and viability; (4) household financial impact; (5) social impact; and (6) responsiveness to equity.

HTAC is actively on the watch for evidence as it is rapidly evolving, and shall update its recommendation when new information becomes available.

Guidance for the General Public: HTAC Guidance for the General Public: COVID-19 Vaccine Sinovac

Guidance for Health Care Providers:  HTAC Guidance for Health Care Providers : COVID-19 Vaccine Sinovac

Evidence summary: SARS-CoV-2 Vaccine (Vero Cell), Inactivated [CoronaVac] for the prevention of COVID-19

HTAC Interim Recommendation Preview: